Format

Send to

Choose Destination
Clin Infect Dis. 2006 Jul 1;43(1):99-102. Epub 2006 May 26.

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

Author information

1
Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia. S.Mallal@murdoch.edu.au.

Abstract

Abacavir therapy is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allele. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients.

PMID:
16758424
DOI:
10.1086/504874
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Bern Open Repository and Information System
Loading ...
Support Center